GENITOURINARY CANCERS

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

Interim data from the LEGEND pivotal cohort show detalimogene achieved complete responses in more than half of patients with BCG-unresponsive non-muscle invasive bladder cancer.

S-HIFU achieved 71% ADT-free survival at 30 months in recurrent prostate cancer post-radiation, with better outcomes in patients with lower PSA and Gleason scores.

The FDA's Oncologic Drugs Advisory Committee voted in favor 7 to 1 that benefits of capivasertib outweighed risks.

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context.

Phase 1 trial of JANX014, a PSMA-targeted T-cell engager, begins in mCRPC, building on prior safety data to expand treatment strategies.

The FDA has granted a priority review to the supplemental biologics license application for enfortumab vedotin/pembrolizumab to all patients with MIBC regardless of cisplatin eligibility.

The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual-masked PSMA-targeting T-cell engager for metastatic prostate cancer.

The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating advanced urothelial carcinoma.

CMS has issued a permanent billing and reimbursement J-code, J9183, for the gemcitabine intravesical system (Inlexzo) in NMIBC.

During the 2026 NCCN Annual Conference, Sandy Srinivas, MD, emphasized that HRR mutation testing in advanced prostate cancer is underutilized.

Historically, treating patients with urothelial carcinoma who were considered cisplatin-ineligible due to insufficient kidney function was a signifcant unmet need; however with enfortumab vedotin entering the frontline space, these patients have another option open to them.

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses practice-changing presentations from the 2026 ASCO GU Cancers Symposium.

Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: traditional chemotherapy or biomarker-driven therapy.

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the noninferiority bar against LHRH agonists.

A wave of innovations across antibody-drug conjugates, synergistic combinations, and expanding biomarkers is transforming the genitourinary cancer landscape from metastatic rescue toward curative, earlier-line paradigms.

The FDA approved a label change for nadofaragene firadenovec-vncg (Adstiladrin) in non–muscle-invasive bladder cancer to improve preparation time.

Nadofaragene firadenovec-vncg (Adstiladrin) received an expanded NCCN recommendation for patients with BCG-unresponsive NMIBC.

Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated mCSPC, demonstrating that targeting DNA damage repair earlier in the disease course substantially delays radiographic progression.

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical guidelines for bladder cancer, according to the manufacturer.